Ocugen (OCGN) Cash from Investing Activities (2014 - 2026)
Ocugen (OCGN) reported Cash from Investing Activities of -$6000.0 for Q1 2026, up 94.12% on a YoY basis from -$3090.9 in Q1 2025, and up 82.86% quarter-over-quarter from -$35000.0 in Q4 2025.
Ocugen (OCGN) Cash from Investing Activities (2014 - 2026) Analysis & Trends
Ocugen has reported Cash from Investing Activities for 13 years, with the latest figure at -$6000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Investing Activities rose 94.12% year-over-year to -$6000.0; the trailing twelve-month figure through Mar 2026 stood at -$215000.0 (up 81.06% YoY), and the FY2025 full-year result was -$311000.0, up 90.81% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$6000.0, up from -$35000.0 in the prior quarter.
- The five-year high for Cash from Investing Activities was $5.7 million in Q2 2023, with the low at -$15.3 million in Q4 2022.
- Historically, Cash from Investing Activities has averaged -$1.0 million across 5 years, with a median of -$102000.0 in 2025.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities tumbled 7866.15% — and 2023, when it surged 1643.05%.
- Ocugen's Cash from Investing Activities stood at -$15.3 million in 2022, then surged by 82.2% to -$2.7 million in 2023, then jumped by 99.52% to -$13000.0 in 2024, then tumbled by 169.23% to -$35000.0 in 2025, then surged by 82.86% to -$6000.0 in 2026.
- The last three Cash from Investing Activities figures came in at -$6000.0 (Q1 2026), -$35000.0 (Q4 2025), and -$86000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 579,519.10 |
| 10 | Ocugen | 411.07 Mn | 411.07 Mn | - | -6,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6,000.00 |
| Mar 31, 2026 | -6,000.00 |
| Dec 31, 2025 | -35,000.00 |
| Dec 31, 2025 | -35,000.00 |
| Sep 30, 2025 | -86,000.00 |
| Sep 30, 2025 | -86,000.00 |
| Jun 30, 2025 | -88,000.00 |
| Jun 30, 2025 | -88,000.00 |
| Mar 31, 2025 | -102,000.00 |
| Mar 31, 2025 | -102,000.00 |
| Dec 31, 2024 | -13,000.00 |
| Dec 31, 2024 | -13,000.00 |
| Sep 30, 2024 | -507,000.00 |
| Sep 30, 2024 | -507,000.00 |
| Jun 30, 2024 | -513,000.00 |
| Jun 30, 2024 | -513,000.00 |
| Mar 31, 2024 | -2.35 Mn |
| Mar 31, 2024 | -2.35 Mn |
| Dec 31, 2023 | -2.72 Mn |
| Dec 31, 2023 | -2.72 Mn |